SCHEMBL6749347

SCHEMBL6749347

C=C1CCN(Cc2ccccc2)C(C)C1

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
ACHE P22303 1/20 0.45
HRH2 P25021 1/20 0.44
SIGMAR1 Q99720 3/20 0.43
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755504 0.82 MAPT (0.45) MAPTACHEHRH2SIGMAR1
SCHEMBL22873345 0.82 MAPT (0.45) MAPTACHEHRH2SIGMAR1
SCHEMBL588654 0.78 SIGMAR1 (0.47) SIGMAR1
SCHEMBL584561 0.78 SIGMAR1 (0.47) SIGMAR1
SCHEMBL584560 0.78 SIGMAR1 (0.47) SIGMAR1
SCHEMBL6205270 0.77 CHRM2 (0.44) MAPTACHESIGMAR1
SCHEMBL6414078 0.77 CHRM2 (0.44) MAPTACHESIGMAR1
SCHEMBL6205376 0.77 CHRM2 (0.44) MAPTACHESIGMAR1
SCHEMBL6205273 0.77 CHRM2 (0.44) MAPTACHESIGMAR1
SCHEMBL6853255 0.77 ACHE (0.56) MAPTACHEHRH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092737-A1 Benzopiperidine derivatives EISAI CO., LTD. 2004-05-13 US disclosed
US-6518423-B1 These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and EISAI CO., LTD. (JP) 2003-02-11 US disclosed
EP-0934941-A1 BENZOPIPERIDINE DERIVATIVES Eisai Co., Ltd. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092737-A1 Benzopiperidine derivatives HLA-DRB1, HRH1, HRH2 MAPT 1257/4885ACHE 2066/4885HRH2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.